• Home
  • >
  • Eris Lifesciences Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/Blinkx_Website/icons/eris-lifesciences-ltd.png Logo

Eris Lifesciences Ltd Financial Statement

Eris Lifesciences Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Dec 2023Sep 2023Jun 2023
Revenue327.85416.68415.31
Operating Expense249.98265.22255.79
Net Profit31.66117.81110.74
Net Profit Margin9.6628.2726.66
Earning Per Share2.338.668.14
EBIDTA80.71171.2159.48
Effective Tax Rate7.4914.4213.63

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Eris Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual1,685.151,347.041,211.86
Operating Expenses Annual1,148.4862.09TBA
Operating Profit Annual547.9511.05TBA
Interest Annual26.174.151.8
Depreciation117.0964.7142.99
Net Profit Annual382.16406.11355.14
Tax Annual30.4836.4139.36

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Eris Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning50.8736.9267.31
Cash Flow from Operations291.74378.26375.36
Cash Flow from Investing-974.61-319.61-323.36
Cash Flow from Financing688.03-44.7-82.4
Cash Flow at the End56.0250.8736.92

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Eris Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)32.5237.9436.26
PBIT Margin (%)25.5833.1432.72
PBT Margin (%)24.3524.4414.66
Net PROFIT Margin (%)29.9134.3231.62
Return On Networth / Equity (%)18.2323.2924.72
Return On Networth /Employed(%)16.6924.4526.81
Return On Assets (%)19.4425.3925.93
Total Debt / Equity(X)0.08TBATBA
Asset Turnover Ratio (%)0.650.740.82

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Eris Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual2,568.45920.93855.43
Total Current Assets Annual764.72627.33467.05
Non Current Assets Annual2,902.611,644.811,367.73
Total Shareholders Funds Annual2,195.991,908.311,576.42
Total Assets Annual3,667.332,272.141,834.78

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Eris Lifesciences Ltd Earning Calls
Dec 2023
EPS beaten by 0.00 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Eris Lifesciences Ltd has a market capitalization of 7,779.44 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Eris Lifesciences Ltd is debt-free with a debt-to-equity ratio of 0.40.

In FY 2023, Eris Lifesciences Ltd recorded a total revenue of approximately 1,661.82 Cr marking a significant milestone in the company's financial performance.

Eris Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.0% and 0.2% annually, respectively..

Eris Lifesciences Ltd's current PE ratio is 20.36.

Eris Lifesciences Ltd's ROCE averaged 20.4% from the FY ending March 2021 to 2023, with a median of 22.3%. It peaked at 24.9% in March 2021, reflecting strong capital efficiency over the period..

Eris Lifesciences Ltd's latest EBIT is Rs. 430.81 Cr, surpassing the average EBIT of Rs. 424.49 Cr over the 5 years..